Rexahn Pharmaceuticals Doses First Patient in a Phase IIa Trial of Supinoxin™ in Patients with Metastatic Triple Negative Breast Cancer
February 23, 2017 09:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., Feb. 23, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), today announced that is has begun enrolling patients into a Phase IIa clinical study of Supinoxin™ in...
Rexahn Pharmaceuticals Presents an Update of the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Pancreatic Cancer at the American Society of Clinical Oncology (ASCO) 2017 Gastrointestinal Cancers Symposium
January 20, 2017 09:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., Jan. 20, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation targeted therapeutics for the...
Rexahn Pharmaceuticals to Present at Biotech Showcase™ 2017
January 03, 2017 09:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., Jan. 03, 2017 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation therapeutics for the treatment of...
Rexahn Pharmaceuticals Reports Third Quarter 2016 Financial Results and Provides Corporate Update
November 07, 2016 09:00 ET
|
Rexahn Pharmaceuticals
Preliminary Efficacy Data from Phase Ib/IIa Clinical Trial of RX-3117 in Metastatic Pancreatic Cancer presented at European Society for Medical Oncology (ESMO) Congress Initiates Stage 2 of the...
Rexahn Pharmaceuticals Receives a Notice of Allowance from the U.S. Patent and Trademark Office for a Patent Covering the Manufacturing of RX-3117 – A Cancer Cell Specific Anticancer Agent
October 31, 2016 09:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., Oct. 31, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing best-in-class therapeutics for the treatment of...
Rexahn Pharmaceuticals Receives U.S. Patent for RX-21101: A Novel Nano-Polymer Conjugate of Docetaxel for the Targeted Treatment of Solid Tumors
October 26, 2016 09:00 ET
|
Rexahn Pharmaceuticals
Rexahn’s proprietary nanotechnology drug conjugate platforms optimize chemotherapy effectiveness and reduce side effect liability ROCKVILLE, Md., Oct. 26, 2016 (GLOBE NEWSWIRE) -- Rexahn...
Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from Phase Ib/IIa Trial of RX-3117 in Metastatic Pancreatic Cancer and Supinoxin™ Phase I Trial at 2016 European Society for Medical Oncology (ESMO) Congress
October 10, 2016 07:00 ET
|
Rexahn Pharmaceuticals
RX-3117 showed Preliminary Efficacy in Pancreatic Cancer Patients for Whom Three or More Prior Therapies had been Ineffective Supinoxin™ was Safe and Well Tolerated in Patients with Advanced...
Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from Phase Ib/IIa Trial of RX-3117 in Metastatic Pancreatic Cancer and Supinoxin™ Phase I Trial at 2016 European Society for Medical Oncology (ESMO) Congress
October 04, 2016 09:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., Oct. 04, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN), a clinical stage biopharmaceutical company developing next generation targeted therapeutics for the...
Rexahn Announces $6 Million Registered Direct Offering
September 14, 2016 09:00 ET
|
Rexahn Pharmaceuticals
ROCKVILLE, Md., Sept. 14, 2016 (GLOBE NEWSWIRE) -- Rexahn Pharmaceuticals, Inc. (NYSE MKT:RNN) today announced it has entered into a definitive agreement with institutional investors to purchase...
Rexahn Pharmaceuticals Initiates stage 2 of Phase Ib/IIa Clinical Trial of RX-3117 in Relapsed or Refractory Metastatic Pancreatic Cancer
September 12, 2016 09:00 ET
|
Rexahn Pharmaceuticals
Predefined Criteria for Preliminary Efficacy Achieved in Pancreatic Cancer Patients for Whom Three Prior Therapies had been Ineffective RX-3117 was Safe and Well Tolerated Results Have Been...